Search

Author/Creator Sand, Michael

1. A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers. (January 2017)

Authors:
Boland, Katja; Moschetti, Viktoria; Dansirikul, Chantaratsamon; Pichereau, Solen; Gheyle, Lien; Runge, Frank; Zimdahl‐Gelling, Heike; Sand, Michael
Journal:
Human psychopharmacology
Issue:
Volume 32:Number 1(2017:Jan.)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. T66. PSYCHOMETRIC VALIDATION OF A NOVEL PATIENT-REPORTED OUTCOME MEASURE FOR ASSESSING PATIENTS' SUBJECTIVE EXPERIENCE OF COGNITIVE IMPAIRMENT OF SCHIZOPHRENIA (PRECIS). (1st April 2018)

Authors:
Rosen, Raymond; Trudeau, Jeremiah; Silverstein, Steven; Henderson, David; Smith, Adam; Walling, David; Garcia, Miguel; Davis, Bethany; Derogatis, Leonard; Sand, Michael
Journal:
Schizophrenia bulletin
Issue:
Volume 44(2018)Supplement 1
Page Start:
S139
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. S252. HEALTH CARE RESOURCE UTILISATION IS HIGHER IN PATIENTS PRIOR TO DIAGNOSIS WITH SCHIZOPHRENIA THAN NON-SCHIZOPHRENIA COMPARATORS IN A LARGE COMMERCIALLY-INSURED POPULATION IN THE UNITED STATES. (1st April 2018)

Authors:
Wallace, Anna; Isenberg, Keith; Barron, John; York, Whitney; Shinde, Mayura; Sidovar, Matt; Franchino-Elder, Jessica; Sand, Michael
Journal:
Schizophrenia bulletin
Issue:
Volume 44(2018)Supplement 1
Page Start:
S425
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗